Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Cardiol Therapeutics stock

CRDL.TO
CA14161Y2006
A2PA9E

Price

2.31
Today +/-
-0.12
Today %
-7.56 %
P

Cardiol Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cardiol Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cardiol Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cardiol Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cardiol Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cardiol Therapeutics Stock Price History

DateCardiol Therapeutics Price
11/19/20242.31 undefined
11/18/20242.49 undefined
11/15/20242.54 undefined
11/14/20242.62 undefined
11/13/20242.66 undefined
11/12/20242.67 undefined
11/11/20242.73 undefined
11/8/20242.78 undefined
11/7/20242.90 undefined
11/6/20242.69 undefined
11/5/20242.72 undefined
11/4/20242.66 undefined
11/1/20242.61 undefined
10/31/20242.50 undefined
10/30/20242.53 undefined
10/29/20242.55 undefined
10/28/20242.57 undefined
10/25/20242.69 undefined
10/24/20242.60 undefined
10/23/20242.58 undefined
10/22/20242.58 undefined
10/21/20242.64 undefined

Cardiol Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cardiol Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cardiol Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cardiol Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cardiol Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cardiol Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cardiol Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cardiol Therapeutics’s growth potential.

Cardiol Therapeutics Revenue, EBIT and net profit per share

DateCardiol Therapeutics RevenueCardiol Therapeutics EBITCardiol Therapeutics Net Income
2029e246.81 M undefined0 undefined118.22 M undefined
2028e160.24 M undefined103.68 M undefined81.9 M undefined
2027e61.25 M undefined22.71 M undefined17.09 M undefined
2026e6.53 M undefined-29.58 M undefined-38.59 M undefined
2025e0 undefined-30.71 M undefined-30.91 M undefined
2024e0 undefined-31.64 M undefined-32.08 M undefined
20230 undefined-29.79 M undefined-28.13 M undefined
20220 undefined-41.34 M undefined-30.93 M undefined
202180,000 undefined-38.66 M undefined-31.64 M undefined
20200 undefined-20.69 M undefined-20.64 M undefined
20190 undefined-14.13 M undefined-13.68 M undefined
20180 undefined-7.1 M undefined-15.89 M undefined
20170 undefined-1.6 M undefined-1.66 M undefined

Cardiol Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000661160246
----------916.67162.3053.75
-------------
0000000000000
-1-15-13-20-31-30-28-32-30-381781118
-1,400.00-13.3353.8555.00-3.23-6.6714.29-6.2526.67-144.74376.4745.68
22.7325.825.8229.8643.2262.5164.46000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Cardiol Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cardiol Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
2.3616.736.9614.0383.959.4734.93
1030101070210142.75
90430920210340270137.12
001.120.02000
0.036.835.370.692.831.490.94
2.4924.0214.3814.9687.1461.4436.15
2030580480360300337.06
0000000
00003412700
720630550460380290210.36
0000000
0000000
0.740.661.130.941.080.860.55
3.2324.6815.5115.988.2262.336.7
             
4.2636.7239.4151.92142.92147.55148.52
01.254.778.7712.6615.5918.79
-1.66-15.96-29.51-47.42-79.34-110.93-139.06
0.260.26004.183.520
0000000
2.8622.2714.6713.2780.4255.7328.25
0.182.140.642.474.869.338.04
00007189850
00006.660.420.24
0000000
005050405015.81
0.182.140.692.5212.2810.798.3
1902701401007020158.53
0000000
0000000
1902701401007020158.53
0.372.410.832.6212.3510.818.45
3.2324.6815.515.8992.7766.5436.7
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cardiol Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cardiol Therapeutics's financial health and stability.

Assets

Cardiol Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cardiol Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cardiol Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cardiol Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-1-15-13-20-31-30
000000
000000
0-5-1805
010327-2
000000
000000
-1-10-11-9-23-27
000000
000000
000000
000000
0120000
314217980
325216930
--1.00--1.00-5.00-
000000
214-9769-24
-1.32-10.9-11.8-9.23-23.56-27.29
000000

Cardiol Therapeutics stock margins

The Cardiol Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cardiol Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cardiol Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cardiol Therapeutics's sales revenue. A higher gross margin percentage indicates that the Cardiol Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cardiol Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cardiol Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cardiol Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cardiol Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cardiol Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cardiol Therapeutics Margin History

Cardiol Therapeutics Gross marginCardiol Therapeutics Profit marginCardiol Therapeutics EBIT marginCardiol Therapeutics Profit margin
2029e98.75 %0 %47.9 %
2028e98.75 %64.7 %51.11 %
2027e98.75 %37.08 %27.91 %
2026e98.75 %-452.95 %-590.81 %
2025e98.75 %0 %0 %
2024e98.75 %0 %0 %
202398.75 %0 %0 %
202298.75 %0 %0 %
202198.75 %-48,325 %-39,550 %
202098.75 %0 %0 %
201998.75 %0 %0 %
201898.75 %0 %0 %
201798.75 %0 %0 %

Cardiol Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Cardiol Therapeutics earnings per share therefore indicates how much revenue Cardiol Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cardiol Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cardiol Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cardiol Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cardiol Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cardiol Therapeutics Revenue, EBIT and net profit per share

DateCardiol Therapeutics Sales per ShareCardiol Therapeutics EBIT per shareCardiol Therapeutics Earnings per Share
2029e3.53 undefined0 undefined1.69 undefined
2028e2.29 undefined0 undefined1.17 undefined
2027e0.88 undefined0 undefined0.24 undefined
2026e0.09 undefined0 undefined-0.55 undefined
2025e0 undefined0 undefined-0.44 undefined
2024e0 undefined0 undefined-0.46 undefined
20230 undefined-0.46 undefined-0.44 undefined
20220 undefined-0.66 undefined-0.49 undefined
20210 undefined-0.89 undefined-0.73 undefined
20200 undefined-0.69 undefined-0.69 undefined
20190 undefined-0.55 undefined-0.53 undefined
20180 undefined-0.28 undefined-0.62 undefined
20170 undefined-0.07 undefined-0.07 undefined

Cardiol Therapeutics business model

Cardiol Therapeutics Inc is an international biopharmaceutical company specializing in the development of innovative therapies for the treatment of heart diseases. The company was founded in 2006 in Canada and has since built a broad portfolio of products and technologies to improve the treatment of heart diseases. The company's business model is based on research and development of innovative therapies that aim to provide patients with more effective treatments for heart diseases. They collaborate closely with renowned research institutions and clinics worldwide to develop a wide range of innovative treatment options. The company has also specialized in the study of cannabinoids for the treatment of heart diseases, focusing on the development of medications tailored to the needs of patients with heart diseases. They have developed CardiolRx, a patented technology based on cannabinoids, which has shown promising results in clinical studies for the treatment of severe heart diseases such as heart failure and myocarditis. Overall, Cardiol Therapeutics Inc is a biopharmaceutical company dedicated to developing therapies for the treatment of heart diseases, with a focus on collaboration, innovative products, and the potential to significantly improve patient care. Cardiol Therapeutics is one of the most popular companies on Eulerpool.com.

Cardiol Therapeutics SWOT Analysis

Strengths

Cardiol Therapeutics Inc has a strong research and development capability, allowing them to innovate and develop novel therapies for cardiovascular diseases.

The company has a dedicated and highly skilled team of scientists and medical professionals who are experts in the field of cardiology.

Cardiol Therapeutics Inc has a robust intellectual property portfolio, which provides them with a competitive advantage and protects their innovations.

Weaknesses

The company is relatively small in size and may have limited financial resources compared to larger pharmaceutical companies, which can hinder their ability to fund extensive clinical trials and commercialize their products.

Cardiol Therapeutics Inc relies heavily on external funding and partnerships for research and development activities, which may introduce uncertainties and dependencies.

Opportunities

There is a growing demand for innovative cardiovascular therapies due to the increasing prevalence of cardiovascular diseases globally, presenting a significant market opportunity for Cardiol Therapeutics Inc.

Advancements in technology and personalized medicine open avenues for the development of targeted therapies, for which Cardiol Therapeutics Inc is well-equipped.

The company can leverage collaborative partnerships with academic institutions, government organizations, and other pharmaceutical companies to gain access to additional resources and expertise.

Threats

The pharmaceutical industry is highly regulated, and obtaining necessary approvals and complying with regulatory requirements can be time-consuming and costly, posing a threat to Cardiol Therapeutics Inc's development timeline and financial stability.

Competition in the cardiovascular therapeutics market is intense with well-established players dominating the industry, making it challenging for Cardiol Therapeutics Inc to gain market share.

External factors such as economic uncertainties, changes in healthcare policies, and global pandemics can impact Cardiol Therapeutics Inc's operations and funding sources.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cardiol Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cardiol Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cardiol Therapeutics shares outstanding

The number of shares was Cardiol Therapeutics in 2023 — This indicates how many shares 64.463 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cardiol Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cardiol Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cardiol Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cardiol Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Cardiol Therapeutics.

Cardiol Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.13 -0.1  (24.59 %)2024 Q2
3/31/2024-0.13 -0.14  (-5.58 %)2024 Q1
12/31/2023-0.12 -0.12  (1.96 %)2023 Q4
9/30/2023-0.12 -0.09  (26.47 %)2023 Q3
6/30/2023-0.13 -0.12  (5.88 %)2023 Q2
3/31/2023-0.15 -0.11  (28.1 %)2023 Q1
12/31/2022-0.16 -0.12  (24.1 %)2022 Q4
9/30/2022-0.15 -0.13  (12.1 %)2022 Q3
6/30/2022-0.14 -0.1  (29.97 %)2022 Q2
3/31/2022-0.17 -0.14  (19.26 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Cardiol Therapeutics stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

32

👫 Social

58

🏛️ Governance

9

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cardiol Therapeutics shareholders

%
Name
Stocks
Change
Date
2.46451 % Tejara Capital Ltd.1,722,24377,8336/30/2024
2.30301 % Merlin Asset Management1,609,385-118,4424/30/2023
2.09922 % AdvisorShares Investments, LLC1,466,972164,9946/30/2024
1.72363 % Elsley (David G)1,204,50050,0006/24/2024
1.32241 % MMCAP Asset Management924,125-1,642,0006/30/2024
1.24007 % Willner (Michael Jay)866,58580,2449/6/2024
0.85859 % Palos Management Inc.600,00008/31/2024
0.66869 % Pekos (Peter)467,29005/13/2024
0.64067 % Hamer (Andrew Warwick M.D.)447,713133,33310/25/2024
0.42925 % Global X Investments Canada Inc.299,967148,5249/30/2024
1
2
3
4
5
...
9

Cardiol Therapeutics Executives and Management Board

Dr. Andrew Hamer(55)
Cardiol Therapeutics Chief Medical Officer, Head of Research and Development
Compensation 868,746
Mr. Christopher Waddick
Cardiol Therapeutics Chief Financial Officer, Corporate Secretary, Director (since 2018)
Compensation 784,127
Mr. Bernard Lim
Cardiol Therapeutics Chief Operating Officer
Compensation 780,139
Mr. David Elsley
Cardiol Therapeutics President, Chief Executive Officer, Director (since 2017)
Compensation 653,800
Dr. Guillermo Torre-Amione
Cardiol Therapeutics Independent Chairman of the Board
Compensation 189,551
1
2
3

Cardiol Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Loblaw Compan Stock
Loblaw Compan
SupplierCustomer0,070,510,11-0,62-0,58-0,37
Seikagaku Stock
Seikagaku
SupplierCustomer-0,170,590,450,770,740,52
1

Most common questions regarding Cardiol Therapeutics

What values and corporate philosophy does Cardiol Therapeutics represent?

Cardiol Therapeutics Inc represents a strong commitment to improving cardiovascular health through innovative therapies. With a core philosophy centered around scientific excellence and patient-centric approach, Cardiol aims to develop safe and effective cannabidiol-based pharmaceuticals. The company focuses on rigorous research and development, clinical trials, and strategic partnerships to deliver breakthrough treatments for heart diseases. By prioritizing the well-being of patients, Cardiol Therapeutics Inc strives to redefine cardiovascular care and contribute to healthier lives.

In which countries and regions is Cardiol Therapeutics primarily present?

Cardiol Therapeutics Inc is primarily present in various countries and regions around the world. The company has a global reach and engages in its operations in multiple places. With its headquarters in Canada, Cardiol Therapeutics Inc has a strong presence in North America, particularly in the United States. Additionally, the company has established partnerships and collaborations globally, allowing it to extend its reach to other regions and countries. Cardiol Therapeutics Inc's commitment to expanding its market presence ensures its innovative healthcare solutions reach patients and healthcare professionals worldwide.

What significant milestones has the company Cardiol Therapeutics achieved?

Cardiol Therapeutics Inc has achieved several significant milestones. The company successfully completed its Phase 2 clinical trial evaluating CardiolRx™ for the treatment of acute myocarditis, a severe inflammatory condition of the heart. Additionally, Cardiol Therapeutics Inc received a patent grant from the United States Patent and Trademark Office for its unique methods in treating various forms of heart failure using cannabinoids. The company also obtained a license agreement with Dalton Pharma Services, a leading contract development and manufacturing organization, to support the production of pharmaceutical-grade cannabidiol. These milestones demonstrate Cardiol Therapeutics Inc's dedication to advancing innovative therapies and solidify its position in the pharmaceutical industry.

What is the history and background of the company Cardiol Therapeutics?

Cardiol Therapeutics Inc. is a pharmaceutical company specializing in the development and commercialization of cutting-edge therapies for cardiovascular diseases. Founded in 2013, Cardiol Therapeutics has quickly emerged as a leader in the field, with a strong focus on cannabinoid-based treatments. The company's innovative research and development efforts have resulted in the development of CardiolRx™, a proprietary pharmaceutical cannabidiol formulation that targets heart diseases. With a relentless dedication to improving patient outcomes, Cardiol Therapeutics is committed to bringing forth effective and safe medicinal solutions for various cardiovascular conditions. They continuously collaborate with leading researchers and medical professionals to advance their mission of revolutionizing cardiovascular care.

Who are the main competitors of Cardiol Therapeutics in the market?

The main competitors of Cardiol Therapeutics Inc in the market include companies like GW Pharmaceuticals, Amarin Corporation, Novartis Pharmaceuticals, and Pfizer Inc.

In which industries is Cardiol Therapeutics primarily active?

Cardiol Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Cardiol Therapeutics?

The business model of Cardiol Therapeutics Inc revolves around the development and commercialization of pharmaceutical products. The company focuses on producing innovative therapies for various medical conditions, particularly those related to heart diseases. Cardiol Therapeutics Inc aims to leverage advanced scientific research and technologies to create effective treatments for cardiovascular disorders. With a strong commitment to improving patients' lives, the company actively engages in clinical trials and collaborations with experts in the field. Cardiol Therapeutics Inc strives to provide solutions that address significant unmet medical needs, positioning itself as a leader in the cardiovascular health industry.

What is the P/E ratio of Cardiol Therapeutics 2024?

The Cardiol Therapeutics P/E ratio is -4.64.

What is the P/S ratio of Cardiol Therapeutics 2024?

The Cardiol Therapeutics P/S ratio is 0.

What is the Quality Investing of Cardiol Therapeutics?

The Quality Investing for Cardiol Therapeutics is 2/10.

What is the revenue of Cardiol Therapeutics 2024?

The revenue cannot currently be calculated for Cardiol Therapeutics.

How high is the profit of Cardiol Therapeutics 2024?

The expected Cardiol Therapeutics profit is -32.08 M CAD.

What is the business model of Cardiol Therapeutics

Cardiol Therapeutics Inc is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cardiovascular diseases. The company is headquartered in Oakville, Ontario and is listed on the Toronto Stock Exchange and the NASDAQ. Cardiol Therapeutics' business model is based on the research, development, and commercialization of novel treatments for cardiovascular system diseases, including chronic heart failure, coronary artery disease, and heart attack. The company focuses on the application of cannabinoids as the basis for its therapeutics. Cardiol Therapeutics' flagship product is the drug candidate CardiolRx, a synthetic cannabidiol (CBD) derivative. It is intended to improve endogenous repair mechanisms after a heart attack. The company has successfully completed the clinical development of CardiolRx; the Phase 3 study (TIMI 3 study) has demonstrated the effectiveness and safety of the drug candidate in patients with heart attack. The approval of CardiolRx is currently being sought from regulatory authorities in the United States and Europe. CardiolRx is being conducted by Cardiol Therapeutics itself. However, CardiolRx is not the only product that Cardiol Therapeutics has in its pipeline. The company has a portfolio of drug candidates that include both synthetic cannabinoids and natural products. Currently, the company is developing another cannabinoid-based medication, CardiolRx + CBD. This product is a combination of the already approved CardiolRx and natural CBD. CardiolRx + CBD is currently undergoing clinical trials. In addition to its pharmaceutical products, Cardiol Therapeutics also operates a research program focused on studying the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to understand the mechanisms of action of cannabinoids on the heart and develop further medical applications. In addition to its research and development work, Cardiol Therapeutics has also entered into partnerships with other companies. In 2019, the company signed an agreement with Apic Bio to jointly develop gene therapy for the treatment of heart failure. Under this agreement, Apic Bio will assist in preparing an Investigational New Drug (IND) submission to the FDA. Cardiol Therapeutics' business model is based on an innovative research platform and a broad pipeline of drug candidates that utilize the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to solidify its leading position in this field and market its products globally. With its experienced management team and strong research results, Cardiol Therapeutics is expected to continue to be successful and have the potential to save lives and improve the health of millions of people worldwide. The main focus of Cardiol Therapeutics is the development of innovative therapies for cardiovascular diseases using cannabinoids. They have successfully completed the clinical development of CardiolRx and are seeking approval for its use in treating heart attack patients. They are also developing other cannabinoid-based medications, such as CardiolRx + CBD. The company also conducts research on the therapeutic effects of cannabinoids on the cardiovascular system. They have partnerships with other companies, such as Apic Bio, to develop gene therapy for heart failure. The company aims to solidify its position in the market and globally market its products.

What is the Cardiol Therapeutics dividend?

Cardiol Therapeutics pays a dividend of 0 CAD distributed over payouts per year.

How often does Cardiol Therapeutics pay dividends?

The dividend cannot currently be calculated for Cardiol Therapeutics or the company does not pay out a dividend.

What is the Cardiol Therapeutics ISIN?

The ISIN of Cardiol Therapeutics is CA14161Y2006.

What is the Cardiol Therapeutics WKN?

The WKN of Cardiol Therapeutics is A2PA9E.

What is the Cardiol Therapeutics ticker?

The ticker of Cardiol Therapeutics is CRDL.TO.

How much dividend does Cardiol Therapeutics pay?

Over the past 12 months, Cardiol Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cardiol Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Cardiol Therapeutics?

The current dividend yield of Cardiol Therapeutics is .

When does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cardiol Therapeutics?

Cardiol Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cardiol Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cardiol Therapeutics located?

Cardiol Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cardiol Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cardiol Therapeutics from 11/19/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Cardiol Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Cardiol Therapeutics in the year 2023?

In the year 2023, Cardiol Therapeutics distributed 0 CAD as dividends.

In which currency does Cardiol Therapeutics pay out the dividend?

The dividends of Cardiol Therapeutics are distributed in CAD.

All fundamentals about Cardiol Therapeutics

Our stock analysis for Cardiol Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardiol Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.